Logo
Nazad
F. Arce Vargas, A. Furness, K. Litchfield, K. Joshi, R. Rosenthal, E. Ghorani, I. Solomon, Marta H. Lesko, N. Ruef, C. Roddie, J. Henry, L. Spain, Assma Ben Aissa, A. Georgiou, Y. Wong, Myles J. Smith, D. Strauss, A. Hayes, D. Nicol, T. O'brien, L. Mårtensson, A. Ljungars, I. Teige, B. Frendéus, Kevin Alan Andrew Nicholas Harrington Melcher Wotherspoon Francis, K. Harrington, A. Melcher, A. Wotherspoon, N. Francis, Ben Archana Steve Ashish Lisa Joanna Sarah Simon Karen Challacombe Fernando Hazell Chandra Pickering Lync, B. Challacombe, A. Fernando, S. Hazell, A. Chandra, L. Pickering, Joanna Lynch, S. Rudman, S. Chowdhury, K. Harrison-Phipps, Mary Varia, C. Horsfield, A. Polson, G. Stamp, M. O'Donnell, W. Drake, Peter Hill, D. Hrouda, E. Mayer, J. Olsburgh, G. Kooiman, K. O'Connor, G. Stewart, M. Aitchison, Maxine G. B. Tran, N. Fotiadis, H. Verma, J. López, Jason Fiona Malgorzata Richard Haydn Helen Dean Jacqui J Lester Morgan Kornaszewska Attanoos Adams Davies F, J. Lester, Fiona Morgan, M. Kornaszewska, R. Attanoos, Haydn Adams, H. Davies, D. Fennell, J. Shaw, J. Le Quesne, A. Nakas, S. Rathinam, W. Monteiro, H. Marshall, Louise Nelson, J. Bennett, Joan Riley, L. Primrose, L. Martinson, G. Anand, S. Khan, M. Nicolson, K. Kerr, Shirley Palmer, H. Remmen, Joy Miller, K. Buchan, M. Chetty, L. Gomersall, S. Lock, B. Naidu, G. Langman, S. Trotter, M. Bellamy, H. Bancroft, A. Kerr, S. Kadiri, J. Webb, G. Middleton, M. Djearaman, Y. Summers, R. Califano, P. Taylor, R. Shah, P. Krysiak, K. Rammohan, E. Fontaine, R. Booton, M. Evison, P. Crosbie, Stuart Moss, F. Idries, Juliette Novasio, L. Joseph, P. Bishop, A. Chaturvedi, Anne Marie Quinn, H. Doran, A. Leek, P. Harrison, K. Moore, Rachael Waddington, F. Blackhall, J. Rogan, E. Smith, C. Dive, G. Brady, D. Rothwell, Sakshi Gulati, Francesca Chemie, J. Tugwood, J. Pierce, D. Lawrence, M. Hayward, N. Panagiotopoulos, Robert S George, D. Patrini, M. Falzon, E. Borg, R. Khiroya, M. Jamal-Hanjani, G. Wilson, Nicolai Juul Birkbak, T. Watkins, N. Mcgranahan, C. Abbosh, S. Horswell, R. Mitter, M. Escudero, A. Stewart, A. Rowan, C. Hiley, J. Goldman, Asia Ahmed, Magali N. Taylor, Junaid Choudhary, P. Shaw, Raju Veeriah, J. Czyzewska-Khan, Diana H. Johnson, J. Laycock, R. Hynds, Mariana Werner Sunderland, J. Reading, M. Novelli, D. Oukrif, S. Janes, M. Forster, T. Ahmad, Siow Ming Lee, P. van Loo, Javier Herrero, J. Hartley, Richard Kevin Stone, Tamara Denner, Marta Costa, Sharmin Begum, B. Phillimore, T. Chambers, E. Nye, S. Ward, G. Elgar, M. Al-Bakir, D. Carnell, R. Mendes, J. George, N. Navani, D. Papadatos-Pastos, M. Scarci, Pat Gorman, H. Lowe, L. Ensell, D. Moore, M. Mackenzie, M. Wilcox, Harriet Bell, A. Hackshaw, Y. Ngai, Sean Smith, N. Gower, C. Ottensmeier, S. Chee, Benjamin Johnson, A. Alzetani, E. Shaw, E. Lim, P. De Sousa, Monica Tavares Barbosa, A. Nicholson, A. Bowman, S. Jordan, A. Rice, H. Raubenheimer, C. Proli, Maria Elena Cufari, John Carlo Ronquillo, Angela Kwayie, H. Bhayani, Morag Hamilton, Yusura Bakar, N. Mensah, L. Ambrose, A. Devaraj, S. Buderi, J. Finch, L. Azcárate, Hema Chavan, Sophie Green, Hillaria Mashinga, K. Lau, M. Sheaff, P. Schmid, J. Conibear, V. Ezhil, V. Prakash, S. Danson, J. Bury, J. Edwards, Jennifer Hill, S. Matthews, Yota Kitsanta, K. Suvarna, M. Shackcloth, J. Gosney, P. Postmus, Sarah L. Feeney, Julius Asante-Siaw, P. Russell, T. Light, T. Horey, K. Blyth, C. Dick, A. Kirk, M. Pule, T. Marafioti, M. Gore, J. Larkin, S. Turajlic, C. Swanton, K. Peggs, S. Quezada
541 9. 4. 2018.

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Summary With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion in vivo, increasing the CD8+ to Treg cell ratio and promoting tumor rejection. Antibodies with improved FcγR binding profiles drove superior anti-tumor responses and survival. In patients with advanced melanoma, response to ipilimumab was associated with the CD16a-V158F high affinity polymorphism. Such activity only appeared relevant in the context of inflamed tumors, explaining the modest response rates observed in the clinical setting. Our data suggest that the activity of anti-CTLA-4 in inflamed tumors may be improved through enhancement of FcγR binding, whereas poorly infiltrated tumors will likely require combination approaches.


Pretplatite se na novosti o BH Akademskom Imeniku

Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo

Saznaj više